What are the stages of medical device product development?

Medical device product development is typically organized into five phases: concept and feasibility, design and development, verification and validation, regulatory submission and design transfer, and commercial launch with post-market surveillance. Each phase has planned inputs, activities, outputs, and a gate review that authorizes proceeding to the next phase.

What is a stage-gate process in medical device development?

A stage-gate process divides device development into distinct phases (stages) separated by formal decision checkpoints (gates). At each gate, leadership reviews the evidence produced in the preceding stage and decides whether the program is ready to proceed, requires additional work, or should be terminated. Stage-gates reduce the cost of failure by catching problems early, when changes are less expensive.

What FDA regulation governs the medical device development process?

Design and development for medical devices is governed by 21 CFR Part 820 (the QMSR), effective February 2, 2026. The QMSR incorporates ISO 13485:2016 by reference at 21 CFR 820.10(c). The design and development requirements are in ISO 13485:2016 Clause 7.3 and its subclauses. The Design History File requirement is maintained through Clause 7.3.10.

What is the difference between design verification and design validation?

Design verification (ISO 13485:2016 Clause 7.3.6) confirms that design outputs meet design inputs under controlled conditions. It answers: did we build the device according to its specifications? Design validation (Clause 7.3.7) confirms that the device works for the intended user under intended use conditions. It answers: did we build the right device? Both are required, and both must be documented in the Design History File.

How does a startup build a QMS for device development?

Medical device startups need a QMS in place before formal design and development begins, because the QMS provides the document control, change control, and training infrastructure within which design controls operate. Many early-stage companies start with a scaled QMS appropriate to their development phase and scale up as they approach V&V and submission. ISO 13485:2016 is the international standard used globally; the FDA's QMSR (effective February 2, 2026) incorporates it by reference.

What comes after V&V in the device development process?

After successful V&V, teams prepare their regulatory submission (510(k), De Novo, or PMA depending on device class), complete design transfer to manufacturing, and prepare for commercial launch. Once commercial, the quality system transitions into post-market mode: complaint handling, adverse event reporting, CAPA, and for EU MDR devices, formal Post-Market Surveillance and Post-Market Clinical Follow-up programs.

Medical Device New Product Development Process: A Stage-Gate Overview

Q: What is design transfer in medical device development?

Design transfer is the process of translating the verified and validated design into the specifications and procedures needed for manufacturing. ISO 13485:2016 Clause 7.3.8 requires documented procedures for transfer and confirmation that production processes can reproduce the validated design. The outputs of design transfer become the Device Master Record (DMR).

Direct answer: Medical device new product development (NPD) moves through five broad phases: concept and feasibility, design and development, verification and validation (V&V), design transfer to manufacturing, and commercial launch. Each phase has defined entry criteria, activities, and exit criteria that connect to FDA's QMSR design controls requirements (21 CFR 820.10(c), ISO 13485:2016 Clause 7.3, effective February 2, 2026) and the submission pathway required for the device's risk class. The full process is documented in the Design History File (DHF), which spans from first formal design inputs through design transfer. (As of July 2026.)

Building a medical device is not a linear march from idea to product. It is a structured process of reducing technical, regulatory, and clinical risk at each stage before committing resources to the next one. A stage-gate model formalizes that logic. Each "gate" is a decision point where leadership reviews the evidence from the current phase and authorizes proceeding.

This article maps the end-to-end process for a typical regulated medical device. It is also the connective hub for the rest of Buzzbox Media's Growth Library Module 4, which covers each stage in detail.

Why Stage-Gates Matter in Regulated Device Development

FDA's design controls framework, now governed under the QMSR (effective February 2, 2026) via ISO 13485:2016 Clause 7.3, requires formal design reviews at planned stages in the development process. A design review is a documented evaluation by qualified personnel, including at least one person independent of the function being reviewed, to determine whether design results meet requirements and identify problems.

The stage-gate model gives the design review process its practical structure. Gates also serve as internal risk checkpoints: if a device cannot pass a gate because a critical technical or regulatory question is unresolved, it is better to discover that at a gate than after a failed V&V campaign or a refused regulatory submission.

The Five Phases of Medical Device NPD

Phase 1: Concept and Feasibility

Objective: Establish that a device idea is technically feasible, clinically meaningful, and commercially viable, and that a regulatory pathway exists.

Key activities in this phase include Voice of Customer (VOC) research to identify the clinical problem and user requirements, preliminary technology assessment and proof-of-concept prototyping, competitive and regulatory landscape review (device classification, predicate analysis, submission pathway), initial risk identification (hazards, severity, rough probability), and business case and funding assessment.

For detail on how to validate the device idea before committing design resources, see How to Validate a Medical Device Idea and Identifying Unmet Clinical Needs in the Growth Library.

Gate 1 criteria: Is the clinical need real? Does a viable regulatory pathway exist? Does the commercial opportunity justify development investment?

Phase 2: Design and Development

Objective: Define what the device must do (design inputs), build and iterate prototypes, and generate initial evidence that designs meet requirements.

This is the heart of the design controls process under ISO 13485:2016 Clause 7.3. Key activities include establishing formal design inputs (functional, performance, safety, usability, and regulatory requirements), alpha and bench prototype development with documented change control, risk analysis updates as the design evolves (managed under ISO 14971:2019), human factors formative evaluations to identify and address use errors, design reviews at planned sub-stages (subsystem, integrated system), and establishing design outputs (drawings, specifications, BOMs) that will become the basis for the Device Master Record (DMR).

For detail on each of these areas, see Medical Device Design Controls, Medical Device Prototyping, Medical Device Design History File (DHF), Risk Management for Medical Devices (ISO 14971), and Human Factors Engineering for Medical Devices.

Gate 2 criteria: Are design inputs complete and approved? Is the design architecture stable? Do bench prototype results support proceeding to formal V&V planning?

Phase 3: Verification and Validation (V&V)

Objective: Generate objective evidence that the device as designed meets its specifications (verification) and that it works safely and effectively for the intended user and use (validation).

This is often the longest phase for novel devices. Key activities include executing documented verification test protocols on production-equivalent or pre-production units; design validation, including human factors validation (summative evaluation) under FDA guidance on human factors and IEC 62366; biocompatibility testing per ISO 10993 if human contact is involved; sterilization validation for sterile devices (ISO 11135:2014/Amd.1:2018 for EO, ISO 11137-1:2025 for radiation, ISO 17665:2024 for steam, or ISO 22441:2022 for VHP, depending on method); shelf life and package validation (ISO 11607-1:2019 and ISO 11607-2:2019); software verification and validation, if applicable (IEC 62304:2006/Amd.1:2015 software life cycle); risk management file update, including benefit-risk analysis; and compilation and internal review of the DHF to confirm completeness.

For detail on V&V, see Design Verification and Validation for Medical Devices. For sterilization validation, see Medical Device Sterilization Validation Guide.

Gate 3 criteria: Do V&V results demonstrate the device meets all design inputs? Is the risk management file complete and approved? Is the DHF ready for regulatory submission?

Phase 4: Regulatory Submission and Design Transfer

Objective: Submit for regulatory clearance or approval and transfer validated design specifications to manufacturing.

These two activities often run in parallel. Design transfer is the process by which design outputs (drawings, specifications, SOPs) are formally translated into the manufacturing process and documented in the Device Master Record (DMR). ISO 13485:2016 Clause 7.3.8 requires documented procedures for design transfer and confirmation that production processes can produce devices that meet design specifications.

Regulatory submission is covered in detail in the 510(k) Submission Process, PMA vs 510(k) vs De Novo, and FDA Pre-Submission (Q-Sub) Meeting articles in this Growth Library.

Key considerations for design transfer:

Transfer must be documented, not assumed. A Transfer Review confirms that the manufacturing process produces devices meeting specifications.
Process validation (ISO 13485:2016 Clause 7.5.6) is required for any manufacturing process whose output cannot be fully verified by inspection alone.
Design for manufacturability (DFM) work done earlier in development (see Design for Manufacturability for Medical Devices) reduces transfer risk.

Gate 4 criteria: Is the regulatory submission submitted (or clearance received, depending on timeline)? Is the DMR complete and approved? Has a manufacturing readiness review been completed?

Phase 5: Commercial Launch and Post-Market Surveillance

Objective: Initiate commercial production, enter the market, and establish post-market surveillance to capture real-world performance data.

Under ISO 13485:2016 and applicable FDA post-market requirements, manufacturers must maintain a quality system that includes complaint handling, adverse event reporting, and corrective and preventive action (CAPA) processes. For EU MDR-registered devices, a Post-Market Surveillance (PMS) plan and Post-Market Clinical Follow-up (PMCF) program are required from launch, particularly for implantable and Class III devices.

Design changes that emerge from post-market data are handled through the change control process and may require regulatory notification or submission depending on the nature of the change.

Gate 5 (ongoing): Is post-market data being captured and reviewed? Are complaint rates within acceptable limits? Is the risk management file being updated based on real-world experience?

How Long Does the Process Take?

There is no universal timeline. Several factors drive duration:

Factor	Shorter Development	Longer Development
Device class	Class I/II	Class III
Submission type	510(k) with clear predicate	PMA with clinical trial required
Technology novelty	Incremental design	Novel mechanism of action
Team experience	Regulatory-experienced team	First-time device team
Manufacturing readiness	Existing process capability	New processes requiring validation

A Class II 510(k) device with an experienced team and a clear predicate, where bench and simulated-use data are sufficient, might reach submission in 18 to 36 months from formal design start. A Class III PMA device requiring a pivotal clinical trial can take five to ten years or more from concept to approval. Device class is a strong predictor of whether clinical data is needed, but it is not absolute: some De Novo and 510(k) devices require clinical data when bench testing cannot resolve a safety or performance question, and some Class III programs rely on well-characterized clinical evidence pathways. The determinant is the evidence question, not the class label alone.

The Role of Quality System Infrastructure

The NPD process does not operate independently of the Quality Management System (QMS). The QMS provides the infrastructure (procedures, document control, change control, training, CAPA) within which the development process runs. Under the QMSR and ISO 13485:2016, the QMS must be in place before design and development activities begin if the device is to be commercialized.

See ISO 13485 Quality Management System for Medical Device Startups for a foundational overview of how to stand up a QMS that supports development.

How Buzzbox Media Fits Into the Device Development Journey

Medical device companies in active development are simultaneously building their device, building their commercial team, and beginning to build market presence. Buzzbox Media helps medtech companies develop search visibility and content strategies that reach the clinical, investor, and commercial audiences relevant to each stage of development. See our medical device marketing services to understand how content and search strategy can support your commercial goals.